Patents Examined by Arthur S Leonard
  • Assay and medicament
    Patent number: 11339374
    Abstract: The invention relates to defective interfering viruses and defective interfering virus RNAs that are effective as antiviral agents. The invention also relates to methods for identifying defective interfering virus RNAs that can be used as effective antiviral agents.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 24, 2022
    Assignee: The University of Warwick
    Inventors: Nigel J. Dimmock, Andrew J. Easton
  • Modified interleukin 12 and use thereof in preparing drugs for treating tumours
    Patent number: 11306129
    Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent anti-tumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: April 19, 2022
    Assignees: BEIJING BIO-TARGETING THERAPEUTICS TECHNOLOGY INC., Zhengzhou University
    Inventors: Yaohe Wang, Pengju Wang, Lemoine Nick, Dongling Gao
  • Tunable endogenous protein degradation
    Patent number: 11293023
    Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: April 5, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Dennis Buckley, Georg Winter, Andrew J. Phillips, Timothy Heffernan, James Bradner, Justin Roberts, Behnam Nabet
  • Orally administered nanoparticles for gene delivery and pharmaceutical composition containing same
    Patent number: 11266747
    Abstract: The present invention relates to a nanoparticle for oral gene delivery, which is a novel oral gene delivery system capable of regulating blood glucose levels in biological systems and insulin secretion in response to ingested meals. More specifically, the present invention relates to a nanoparticle for gene delivery, comprising: an ionic polymer conjugated with bile acid or a bile acid derivative; and a gene; and to a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: March 8, 2022
    Assignee: KB BIOMED INC.
    Inventors: Yong-Kyu Lee, Dong Yun Lee, Sung Hun Kang, Revuri Vishnu
  • Intracellular genomic transplant and methods of therapy
    Patent number: 11266692
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: March 8, 2022
    Assignees: Regents of the University of Minnesota, Intima Bioscience, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • Methods for nucleic acid capture
    Patent number: 11236325
    Abstract: Solutions, reagents, and methods for nucleic acid purification. In certain aspects, cationic surfactant and, optionally, an anionic surfactant solutions are provided which can be used for phase separation and capture of nucleic acids, such as plasmid or genomic DNA, to a solid phase carrier, such as a mineral matrix.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 1, 2022
    Assignee: ZYMO RESEARCH CORPORATION
    Inventors: Ryan Kemp, Jonathan A. Claypool, Marc E. Van Eden, Xi-Yu Jia
  • Compositions of nucleic acid-containing nanoparticles for in vivo delivery
    Patent number: 11235071
    Abstract: Compositions comprising a polymeric micellar nanoparticle composition comprising a block or graft copolymer comprising at least one polycationic polymer and at least one polyethylene glycol (PEG) polymer having an average molecular weight less than 1 kDa, and at least one nucleic acid, wherein the graft or block copolymer and at least one nucleic acid are complexed and condensed into a shaped micellar nanoparticle that is stable in biological media are disclosed. The presently disclosed subject matter also provides a method for preparing the presently disclosed polymeric micellar nanoparticle compositions, a method for targeting at least one metastatic cancer cell in a subject, and a method for treating a disease or condition using the presently disclosed polymeric micellar nanoparticle compositions.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: February 1, 2022
    Assignee: The Johns Hopkins University
    Inventors: Hai-Quan Mao, John Michael Williford, Maani Archang, Il Minn, Yong Ren, Jose Luis Santos, Martin G. Pomper
  • Histidine engineered light chain antibodies and genetically modified non-human animals for generating same
    Patent number: 11192947
    Abstract: A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon. Methods of making non-human animals that express antibodies comprising a histidine-containing universal light chain are provided.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: December 7, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: John McWhirter, Lynn Macdonald, Andrew J. Murphy
  • Flexible tissue matrix and methods for joint repair
    Patent number: 11185576
    Abstract: A synthetic, flexible tissue matrix and methods for repairing hyaline cartilage defects in a joint using the flexible tissue matrix are described. The flexible tissue matrix includes a high molecular weight polycaprolactone polymer entangled with a polysaccharide such as hyaluronic acid. In the methods, autologous bone mesenchymal stem cells are introduced to a joint by a microfracturing technique, and a membrane made of the flexible matrix is applied to the joint. Cartilage which forms in the joint is hyaline cartilage rather than fibrocartilage.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 30, 2021
    Assignee: Isto Technologies II, LLC
    Inventors: Mitchell S. Seyedin, Anthony J. Ward, Matthew Matava
  • Capped and uncapped RNA molecules and block copolymers for intracellular delivery of RNA
    Patent number: 11179478
    Abstract: The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: November 23, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventor: Bruno Pitard
  • Immunolipoplex nanoparticle biochip containing molecular probes for capture and characterization of extracellular vesicles
    Patent number: 11175286
    Abstract: The present invention disclosed a method of fabricating an antibody immunolipoplex nanoparticle (Ab-ILN) biochip and antibody tethered lipoplex nanoparticle (Ab-TLN) biochip. The aforementioned antibody-based lipoplex nanoparticle biochip or the related array contains molecular probes and is applied for detecting the presence of a disease or condition in a subject obtaining a body fluid sample by capturing and identifying both membrane protein and intra-vesicular DNA/RNA/proteins of extracellular vesicles (EVs).
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: November 16, 2021
    Assignee: SPOT BIOSYSTEMS LTD.
    Inventors: Ly James Lee, Kwang Joo Kwak, Andrew Lee
  • Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
    Patent number: 11136369
    Abstract: This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: October 5, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: H. Trent Spencer, Christopher B. Doering, Brantley R. Herrin, Max Dale Cooper
  • Universal donor cells
    Patent number: 11118195
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: September 14, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
    Patent number: 11116795
    Abstract: The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: September 14, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nicola Mason, Daniel J. Powell, Jr., Mohammed Kazim Panjwani, Jenessa Smith
  • Gene-regulating compositions and methods for improved immunotherapy
    Patent number: 11111493
    Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 7, 2021
    Assignee: KSQ Therapeutics, Inc.
    Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo
  • Synthetic combinatorial AAV capsid library for targeted gene therapy
    Patent number: 11091777
    Abstract: Disclosed are compositions and methods for producing modified adeno-associated virus (AAV) cap genes and combinatorial libraries of chimeric AAV vectors and virions; selecting for virions displaying cell-specific tropisms; and, in certain embodiments, producing helper vectors containing one or more modified AAV cap genes. The synthetic combinatorial AAV capsid libraries of the invention are useful in introducing into selected target host cells one or more nucleic acid molecules. The viral vectors and genetic constructs disclosed herein are also useful in a variety of diagnostic and/or therapeutic gene-therapy regimens.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: August 17, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Damien Marsic, Sergei Zolotukhin, Mavis Agbandje-McKenna
  • Methods for inducing selective apoptosis
    Patent number: 11077176
    Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: August 3, 2021
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventor: Malcolm K. Brenner
  • Modulation of ciliogenesis
    Patent number: 11077131
    Abstract: The disclosure is based on the finding that compounds capable of binding to (or interacting with) chromatin binding/remodelling complexes (for example Polycomb group PRC1 and Trithorax group MLL) and/or modulation of the same can be used to modulate (for example switch on/off) ciliogenesis as may occur, for example, in the human pulmonary bronchial epithelium. Provided are compounds, compositions, methods and medicaments which may be used to treat and/or prevent diseases and/or conditions associated with aberrant or defective ciliogenesis.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 3, 2021
    Assignee: Academisch Ziekenhuis Leiden a/u Leiden University Medical Center
    Inventor: Ronald Karel Louisa Van Brempt
  • Bubble-jetting chip, localized ablation device and localized ablation method, and injection device and injection method
    Patent number: 11053472
    Abstract: The present invention enables fabrication and mass production of a bubble-jetting chip that includes a desired number of bubble jetting portions of the same size having bubble-jetting outlets of the same size. Mass production is enabled by fabricating a bubble-jetting chip comprising a substrate and a bubble-jetting portion formed on the substrate, the bubble-jetting portion comprising: an electrode that is formed of a conductive material; an insulating portion that is formed of an insulating photosensitive resin, is provided so as to sandwich the electrode, and includes an extended section that extends beyond the tip of the electrode; and a space that is formed between the extended section of the insulating portion and the tip of the electrode.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: July 6, 2021
    Assignee: Japan Science and Technology Agency
    Inventors: Yoko Yamanishi, Yohei Hamano, Takuya Kambayashi
  • Mechanical transfection devices and methods
    Patent number: 11046976
    Abstract: Systems and methods for transfection devices are contemplated for delivery of various complex macrostructures. Preferred systems and methods are suitable for mRNA reprogramming and genome editing and use mechanical force to induce uptake of the macrostructures in a target cell. Contemplated devices are able to achieve high throughput of transfected cells in remarkably short time that remain viable and are capable of producing colonies.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 29, 2021
    Assignee: NanoCav, LLC
    Inventor: Ting Wu